Haematologica

Haematologica www.haematologica.org publishes novel findings in basic, clinical and translational hematology research. Impact Factor (JCR) 7.116 (7th of 76)

Haematologica/The Hematology Journal (pISSN: 0390-6078, eISSN: 1592-8721, NLM ID: 0417435) publishes peer-reviewed papers across all areas of experimental and clinical hematology. The journal is owned by a non-profit organization, the Ferrata Storti Foundation, and serves the scientific community strictly following the International Committee of Medical Journal Editors (ICMJE, www.icmje.org) recom

mendations on publication ethics policies for medical journals. Haematologica was founded in 1920 by Adolfo Ferrata

Come and visit us at booth B4.04! 📍Grab your bag and our 2026 Special Edition – completely free! 🎁✨See you there! 👋
11/06/2026

Come and visit us at booth B4.04! 📍
Grab your bag and our 2026 Special Edition – completely free! 🎁✨
See you there! 👋

Locally manufactured versus commercial CAR T in large B-cell lymphoma.As CAR T-cell therapy expands globally, questions ...
10/06/2026

Locally manufactured versus commercial CAR T in large B-cell lymphoma.
As CAR T-cell therapy expands globally, questions remain regarding the comparative performance of locally manufactured and commercial products. A new multicenter propensity score-matched analysis examines outcomes in patients with large B-cell lymphoma, addressing a key issue in accessibility, scalability, and real-world cellular therapy practice.
https://haematologica.org/article/view/13066

Predicting thrombo-ischemic risk in acute promyelocytic leukemia.Despite major therapeutic advances, thrombo-ischemic co...
07/06/2026

Predicting thrombo-ischemic risk in acute promyelocytic leukemia.

Despite major therapeutic advances, thrombo-ischemic complications remain a serious concern in acute promyelocytic leukemia. In the PETHEMA/PALG study, investigators developed a scoring system aimed at identifying patients at higher risk of life-threatening thrombo-ischemic events, addressing an important challenge in risk stratification and supportive care. Find the results in Haematologica
https://haematologica.org/article/view/12989

Targeting RNA-binding proteins in leukemia. RNA-binding proteins are emerging as promising therapeutic targets in hemato...
05/06/2026

Targeting RNA-binding proteins in leukemia.
RNA-binding proteins are emerging as promising therapeutic targets in hematologic malignancies. The RNA-binding protein IGF2BP3 is an oncofetal protein over-expressed in B-cell acute lymphoblastic leukemia and is critical for leukemogenesis in experimental models. A new study investigates a small molecule inhibitor of IGF2BP3, exploring how disruption of RNA regulatory networks may affect leukemic cell survival and open new avenues for targeted therapy in leukemia. Read more in Haematologica.
https://haematologica.org/article/view/13016

Idiopathic multicentric Castleman disease (iMCD) encompasses biologically distinct subtypes with variable inflammatory p...
31/05/2026

Idiopathic multicentric Castleman disease (iMCD) encompasses biologically distinct subtypes with variable inflammatory profiles. The two major clinical subtypes are idiopathic plasmacytic lymphadenopathy (IPL) and iMCD with thrombocytopenia, anasarca, fever, renal dysfunction/reticulin fibrosis, and organomegaly (TAFRO). A new study examines interleukin-6 production in IPL and TAFRO subtypes, exploring differences in cytokine regulation and their implications for disease classification and therapeutic strategies.
https://haematologica.org/article/view/12273

Mantle cell lymphoma (MCL) remains a challenging and generally incurable disease. Treatment outcomes in MCL have evolved...
29/05/2026

Mantle cell lymphoma (MCL) remains a challenging and generally incurable disease. Treatment outcomes in MCL have evolved substantially over the past decades. A pooled analysis of six randomized phase III trials (1996–2020) examines survival trends in patients ≤65 years with advanced-stage disease, addressing how therapeutic advances have reshaped long-term outcomes in this population. Read more in Haematologica
https://haematologica.org/article/view/12967

Despite standard treatment with hypomethylating agents, the prognosis of patients with higher-risk myelodysplastic syndr...
27/05/2026

Despite standard treatment with hypomethylating agents, the prognosis of patients with higher-risk myelodysplastic syndrome (MDS) remains poor and treatment strategies must evolve. A new multicenter, randomized controlled trial compares decitabine plus all-trans retinoic acid with decitabine monotherapy, examining whether combination approaches may refine outcomes in this high-risk patient population. Read the results in Haematologica.
https://haematologica.org/article/view/13003

Donor selection in allogeneic transplantation: does age matter? Donor selection remains a cornerstone of allogeneic hema...
25/05/2026

Donor selection in allogeneic transplantation: does age matter? Donor selection remains a cornerstone of allogeneic hematopoietic stem cell transplantation, yet priorities may shift across different patient populations. A new study explores age-related differences in donor selection strategies, examining how clinical decision-making may vary and what this means for optimizing transplant outcomes.
https://haematologica.org/article/view/12269

The clearance of red blood cells is a tightly controlled process central to hematologic homeostasis. This study investig...
23/05/2026

The clearance of red blood cells is a tightly controlled process central to hematologic homeostasis. This study investigates the role of ALX/FPR2 signaling in splenic erythrophagocytosis, exploring how immune pathways regulate red cell turnover and contribute to physiological and pathological processes.
https://haematologica.org/article/view/12270

Indirizzo

Via Giuseppe Belli 4
Pavia
27100

Orario di apertura

Lunedì 09:00 - 18:00
Martedì 09:00 - 18:00
Mercoledì 09:00 - 18:00
Giovedì 09:00 - 18:00
Venerdì 09:00 - 18:00

Telefono

+39038227129

Sito Web

Notifiche

Lasciando la tua email puoi essere il primo a sapere quando Haematologica pubblica notizie e promozioni. Il tuo indirizzo email non verrà utilizzato per nessun altro scopo e potrai annullare l'iscrizione in qualsiasi momento.

Contatta Lo Studio

Invia un messaggio a Haematologica:

Scelte rapide

In evidenza

Condividi